

Robert M. LORENCE et al  
Appl. No. 08/260,536  
November 10, 2005

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-331 (canceled)

332. (previously presented) A method of treating cancer in a mammal having a tumor comprising administering intravenously to said mammal more than one dose of a live purified Newcastle Disease Virus in an amount sufficient to cause tumor regression.

333. (previously presented) A method as in claim 332 wherein said tumor is selected from the group consisting of: lung carcinoma, breast carcinoma, prostate carcinoma, colon adenocarcinoma, cervical carcinoma, endometrial carcinoma, ovarian carcinoma, bladder carcinoma, Wilm's tumor, fibrosarcoma, osteosarcoma, melanoma, synovial sarcoma, neuroblastoma and glioblastoma.

334. (previously presented) A method as in claim 332 wherein said tumor is a colon adenocarcinoma.

335. (previously presented) A method as in claim 332 wherein said tumor is a melanoma.

336. (previously presented) A method as in claim 332 wherein said tumor is a neuroblastoma.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
November 10, 2005

337. (previously presented) A method as in claim 332 wherein said Newcastle Disease Virus is strain Mass MK107.

338. (previously presented) A method as in claim 332 wherein said Newcastle Disease Virus is strain 73-T.

339-341. (canceled)

342. (previously presented) A method as in claim 332 wherein the amount of Newcastle Disease Virus administered intravenously is about  $4 \times 10^{10}$  to  $4 \times 10^{12}$  PFU/kg.

343-351. (canceled)

352. (previously presented) A method as in claim 332 wherein the Newcastle Disease Virus is administered intravenously in an amount of about  $10^8$  PFU.

353-366 (canceled)

367. (previously presented) A method according to claim 332 further comprising administering a chemotherapeutic agent.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
November 10, 2005

368. (currently amended) A method as in claim 367 where the chemotherapeutic agent is selected from the group consisting of thiotepa, busulfan, cyclophosphamide, methotrexate, cytarabine, bleomycin, cisplatin, doxorubicin, melphalan, mercaptopurine, vinblastine, 5-fluorouracil, ~~taxel~~ paclitaxel, and retinoic acid.

369. (previously presented) A method as in claim 368 where the chemotherapeutic agent is 5-fluorouracil.

370. (previously presented) A method according to claim 332 further comprising administering an immunosuppressive agent.

371. (previously presented) A method as in claim 370 wherein said immunosuppressive agent is a corticosteroid.

372. (previously presented) A method according to claim 332 further comprising administering a cytotoxic or cytostatic agent.

373. (previously presented) A method as in claim 372 wherein said cytotoxic or cytostatic agent is an antibody.

374. (previously presented) A method as in claim 372 wherein said cytotoxic or cytostatic agent is a cytokine.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
November 10, 2005

375-383. (canceled)

384. (previously presented) A method according to claim 332, wherein said Newcastle Disease Virus is essentially free of allantoic fluid.

385. (previously presented) A method according to claim 332, wherein said Newcastle Disease Virus is essentially free of red cells, embryonic membranes and egg shell debris.

386. (previously presented) A method according to claims 332, wherein said Newcastle Disease Virus is purified from cell culture.

387. (previously presented) A method as in claim 332 wherein said tumor is cervical carcinoma.

388-391. (canceled)

392. (currently amended) A method according to claim 332, ~~388 or 389~~ wherein said Newcastle Disease Virus is in the form of a composition which consists essentially of Newcastle Disease Virus.

Robert M. LORENCE et al  
Appl. No. 08/260,536  
November 10, 2005

393. (currently amended) A method according to claim 332, ~~388 or 389~~ wherein said Newcastle Disease Virus is in the form of a composition also comprising a pharmaceutically acceptable carrier.

394. (currently amended) A method according to claim 332, ~~375, 388 or 389~~ wherein said tumor is a human tumor.

395. (currently amended) A method according to claim 332, ~~375, 388 or 389~~ wherein said tumor is greater than 0.6 cm in diameter.

396. (currently amended) A method according to claim 332, ~~375, 388 or 389~~ wherein said tumor is a metastatic tumor.

397. (currently amended) A method according to claim 332, ~~375 or 388~~ wherein said amount administered is sufficient to cause complete tumor regression.

398. (currently amended) A method as in claim 332, ~~375, 388 or 389~~ wherein said Newcastle Disease Virus is a strain of moderate virulence.

399. (currently amended) A method according to claim 332, ~~375, 388 or 389~~ further comprising administering radiation.

400-402. (canceled) .

*Examiner's Amendment*  
*cancel claim 398 - Leonard*  
*MITLAND*  
*approved (11/10/05)*

Robert M. LORENCE et al  
Appl. No. 08/260,536  
November 10, 2005

403. (currently amended) A method according to claims 332, ~~375, 388 or 389~~  
wherein said administering step causes tumor regression.